top of page

The future of pharmaceuticals. 

Laxxon Medical is a global leader of smart drug delivery systems in the pharmaceutical industry, pioneering a new generation of advanced oral drug delivery forms with Laxxon's additive manufacturing technology platform, SPID®-Technology.  Laxxon is dedicated to revolutionizing the pharmaceutical industry by driving innovation with better, smarter drug delivery solutions. 

Laxxon owns the exclusive worldwide rights for the development, production and commercialization for complex drug delivery systems based on our innovative additive manufacturing process. 
 

What we do

Together with our CDMO partner Adare, we are developing advanced oral dosage forms to unlock clinical and commercial opportunities across the world. 

​Laxxon's pipeline includes 4+ ongoing working-projects with notable pharma players, biotech companies and research universities, in addition to 13 in-house assets. Laxxon's IP is continuously growing, and together with the licensed IP from Exentis Group, consists of 230 patents and patent applications with more than 5,500 patent claims.

SPID®-Technology

Based on our technology partner Exentis Group's proprietary 3D screen printing technology platform, Laxxon’s SPID®-Technology (Screen Printing Innovational Drug Technology) is a cutting-edge patented additive manufacturing technology which enables intelligent pharmaceutical application forms, such as oral, transdermal, and implantable dosages, through geometric shaping and heterogeneous distribution of active pharmaceutical ingredients (APIs).

 

SPID®-Technology is capable of printing small batches for R&D, up to commercial-scale production (up to 1.5MM units per day) without the need to change the manufacturing process.

Strategic Commercialization

SPID®-Technology unlocks innovative drug delivery advancements paired with fast-tracked market access and extensive IP protection to yield disruptive opportunities in drug development and commercialization.

Laxxon’s business model is based upon a three-solution framework:

With SPID®-Technology, Laxxon can develop and manufacture advanced versions of new and existing pharmaceutical drugs while extending and adding new patent protection through the technology transfer process. Laxxon can fully utilize the FDA’s 505b(2) regulatory pathway in the US and Hybrid applications under article 10(3) of Directive 2001/83/EC in the EUR, which fast tracks product routes to market.

IMG_0190 copy.png
IMG_0176 copy.JPG
Printer Illustration-2.jpeg
Helmut Kerschbaumer Laxxon Medical

Helmut Kerschbaumer

Chief Executive Officer

Klaus Kuhne Laxxon Medical

Klaus
Kühne

Chief Operations Officer

Alex Ruckdaeschel Laxxon Medical

Alex
Ruckdaeschel

Chief Strategy Officer

Achim Schneeberger Laxxon Medical

Achim
Schneeberger Ph.D

Chief Science Officer

Marjorie Bailey Laxxon Medical

Marjorie
Bailey

Chief Financial Officer

Edward Kay Laxxon Medical

Edward

Kay

Board Member

Victoria Boyle-Hebron Laxxon Medical

Victoria
Boyle-Hebron

Board Member

Board of Directors

Laxxon Lab.png

About Laxxon Medical

Helmut Kerschbaumer

Chief Executive Officer

Klaus Kühne

Chief Operations Officer

Alex Ruckdaeschel

Chief Strategy Officer

Achim Schneeberger Ph.D

Chief Science Officer

LC color pix.png

Lauren Chung, Ph.D

Chief Financial Officer

Laxxon Leadership

Laxxon was founded in 2017 by a team of medical and business professionals with 20+ years of experience in the pharmaceutical industry. Our highly skilled team provides comprehensive pharmaceutical services to pharmaceutical partners including R&D, IP, and regulatory services. Laxxon is headquartered in New York City with research and development facilities in Jena, Germany. 

Board of Directors

Edward Kay

Board Member

Edward W. Kay, Jr., age 65, has been a director of the Vuzix Corporation, manufacturer and sale of VR and optical devices since April 2016, and Lead Independent Director since February 2022. Mr. Kay is a Certified Public Accountant who spent his 33-year career with PricewaterhouseCoopers LLP (PwC) working with companies in various industries...

Victoria Boyle-Hebron

Board Member

Victoria Boyle-Hebron, a Pace University graduate, began her career at The Bank of New York and Dow Jones. After years in the investment banking sector, she co-founded and served as a Managing Director for SLGR, a global gold refinery. An accomplished financial and business professional executive, Victoria has over 20 years of industry experience, facilitating...

Scientific Advisory Board

Ulrich S. Schubert

Ph.D.

Dr. Schubert is a chemist and professor for Organic and Macromolecular Chemistry at the Friedrich Schiller University Jena. Dr. Schubert studied chemistry at the universities of Frankfurt am Main, Virginia Commonwealth University (Richmond, USA) and Bayreuth, before receiving his doctorate from Bayreuth in a joint PhD thesis...

Ulrich Granzer

Ph. D.

Dr. Granzer graduated as a pharmacist in 1984 from the University of Marburg, followed by Ph.D. studies during which he also acted as lecturer for pharmaceutical chemistry. In 1988 he served in the German Air Force and advanced to the rank of a captain with responsibility for drug safety. In 1989, he started his industry career...

Kurt van Scoik

Ph. D.

Dr. Van Scoik studied pharmacy before obtaining his doctorate in pharmaceutics at the University of Wisconsin-Madison in 1987. Dr. Van Scoik gained ten years' experience at Abbott Laboratories in the Pharmaceutical Products Division, where his research involved solving problems related to the development of new drugs and new solid...

bottom of page